Interleukin 15 Provides Relief to CTLs from Regulatory T Cell–Mediated Inhibition: Implications for Adoptive T Cell–Based Therapies for Lymphoma

PURPOSE: Systemic administration of recombinant interleukin (IL)-2 is used to support the expansion and persistence of adoptively transferred antigen-specific CTLs in patients with cancer. However, IL-2 also expands regulatory T cells (Treg) that in turn impair the antitumor activity of CTLs. As rec...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Perna, Serena K., De Angelis, Biagio, Pagliara, Daria, Hasan, Sayyeda T., Zhang, Lan, Mahendravada, Aruna, Heslop, Helen E., Brenner, Malcolm K., Rooney, Cliona M., Dotti, Gianpietro, Savoldo, Barbara
Formato: Artigo
Lenguaje:Inglês
Publicado: 2012
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3693218/
https://ncbi.nlm.nih.gov/pubmed/23149818
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-12-2143
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares